Page last updated: 2024-12-04

carbamyl phosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Carbamyl phosphate is a crucial intermediate in the biosynthesis of both pyrimidines and arginine. It is synthesized in two distinct pathways: 1) de novo synthesis by carbamoyl phosphate synthetase I (CPS I) in mitochondria, which utilizes ammonia, bicarbonate, and ATP, and 2) by carbamoyl phosphate synthetase II (CPS II) in the cytosol, which uses glutamine as the nitrogen source. Carbamyl phosphate is a key component of the urea cycle, where it is utilized to eliminate excess nitrogen from the body. It is also essential for the synthesis of pyrimidines, which are crucial building blocks of DNA and RNA. The study of carbamyl phosphate is significant due to its central role in metabolism and its implications in various metabolic diseases, including urea cycle disorders and pyrimidine biosynthesis defects. Understanding its synthesis, regulation, and role in different pathways is essential for developing diagnostic and therapeutic strategies for these disorders.'

Carbamyl Phosphate: The monoanhydride of carbamic acid with PHOSPHORIC ACID. It is an important intermediate metabolite and is synthesized enzymatically by CARBAMYL-PHOSPHATE SYNTHASE (AMMONIA) and CARBAMOYL-PHOSPHATE SYNTHASE (GLUTAMINE-HYDROLYZING). [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID278
CHEMBL ID369105
CHEBI ID17672
SCHEMBL ID50374
MeSH IDM0003330

Synonyms (31)

Synonym
monocarbamoyl phosphate
phosphoric acid mono(formamide)ester
aminocarbonyl dihydrogen phosphate
CHEBI:17672 ,
carbamyl phosphate
carbamic phosphoric monoanhydride
carbamoyl dihydrogen phosphate
methanol, aminooxo-, dihydrogen phosphate (ester)
phosphono carbamate
carbamoyl phosphate
carbamyl-phosphate
C00169
590-55-6
CARBAMOYL-P ,
bdbm50162819
CHEMBL369105 ,
carbamoylphosphate
AKOS006341689
carbamic acid, monoanhydride with phosphoric acid
gc5kzw01q3 ,
unii-gc5kzw01q3
SCHEMBL50374
(carbamoyloxy)phosphonic acid
carbamoyl phosphoric acid
carbamoyl-phosphate
carbamic acid monoanhydride with phosphoric acid
carbamic acid monoanhydride with phosphorate
Q424409
carbamic acid, anhydride with phosphoric acid (1:1)
DTXSID70862253
EN300-6732413

Research Excerpts

Overview

Carbamyl phosphate is an inhibitor of the formyltetrahydrolfolate synthetase forward reaction. It is a potential intermediate in the normal enzymic reaction.

ExcerptReferenceRelevance
"Carbamyl phosphate is an inhibitor of the formyltetrahydrolfolate synthetase forward reaction, and formate as well as phosphate inhibit the ATP synthesis reaction."( Carbamyl phosphate-dependent ATP synthesis catalyzed by formyltetrahydrofolate synthetase.
Balfe, CA; Buttlaire, DH; Himes, RH; Wendland, MF, 1979
)
2.42
"Carbamyl phosphate is an analog of formyl phosphate-a potential intermediate in the normal enzymic reaction."( Formyltetrahydrofolate synthetase-catalyzed formation of ATP from carbamyl phosphate and ADP. Evidence for a formyl phosphate intermediate in the enzyme's catalytic mechanism.
Buttlaire, DH; Himes, RH; Reed, GH, 1976
)
1.21

Actions

ExcerptReferenceRelevance
"Carbamyl phosphate produced an increase in Vmax."( Interaction of acetyl phosphate and carbamyl phosphate with plant phosphoenolpyruvate carboxylase.
Andreo, CS; Gonzalez, DH; Iglesias, AA, 1987
)
1.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
acyl monophosphateAn organic phosphate ester or anhydride formed by condensation of phosphoric acid with a carboxylic acid.
one-carbon compoundAn organic molecular entity containing a single carbon atom (C1).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (51)

PathwayProteinsCompounds
Pyrimidine Metabolism2353
Urea Cycle1325
Aspartate Metabolism1430
Arginine and Proline Metabolism2047
Glutamate Metabolism2244
Ammonia Recycling1227
4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency2244
Homocarnosinosis2244
Hyperinsulinism-Hyperammonemia Syndrome2244
Prolidase Deficiency (PD)2047
Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency)2047
Hyperprolinemia Type II2047
Hyperprolinemia Type I2047
Prolinemia Type II2047
Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency)2047
Ornithine Aminotransferase Deficiency (OAT Deficiency)2047
Canavan Disease1430
Hypoacetylaspartia1430
Argininemia1325
Argininosuccinic Aciduria1325
Citrullinemia Type I1325
Ornithine Transcarbamylase Deficiency (OTC Deficiency)1325
beta-Ureidopropionase Deficiency2353
UMP Synthase Deficiency (Orotic Aciduria)2353
Dihydropyrimidinase Deficiency2353
MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy)2353
Carbamoyl Phosphate Synthetase Deficiency1325
2-Hydroxyglutric Aciduria (D and L Form)2244
Creatine Deficiency, Guanidinoacetate Methyltransferase Deficiency2047
Hyperornithinemia with Gyrate Atrophy (HOGA)2047
Hyperornithinemia-Hyperammonemia-Homocitrullinuria [HHH-syndrome]2047
L-Arginine:Glycine Amidinotransferase Deficiency2047
Succinic Semialdehyde Dehydrogenase Deficiency2244
Arginine Metabolism2848
Allantoin Degradation (Anaerobic)518
Alanine,Aspartic acid and Asparagine metabolism ( Alanine,Aspartic acid and Asparagine metabolism )2237
Arginine and Proline metabolism ( Arginine and Proline metabolism )4255
Glutamic acid and Glutamine metabolism ( Glutamic acid and Glutamine metabolism )1926
Pyrimidine Nucleotides and Nucleosides metabolism ( Pyrimidine Nucleotides and Nucleosides metabolism )4549
Metabolic Epileptic Disorders2589
uridine-5'-phosphate biosynthesis018
pyrimidine ribonucleotides de novo biosynthesis022
arginine biosynthesis I027
superpathway of histidine, purine, and pyrimidine biosynthesis064
Metabolism overview078
Biochemical pathways: part I0466
Amino acid metabolism094
Pyrimidine metabolism038
Urea cycle and metabolism of amino groups2116
Arginine biosynthesis526
Arginine biosynthesis II (acetyl cycle)425
De novo synthesis of UMP221

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 4Homo sapiens (human)Ki9.90000.00021.97209.9200AID238915
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
bicarbonate transportCarbonic anhydrase 4Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
protein bindingCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 4Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (15)

Processvia Protein(s)Taxonomy
basolateral plasma membraneCarbonic anhydrase 4Homo sapiens (human)
rough endoplasmic reticulumCarbonic anhydrase 4Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentCarbonic anhydrase 4Homo sapiens (human)
Golgi apparatusCarbonic anhydrase 4Homo sapiens (human)
trans-Golgi networkCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
external side of plasma membraneCarbonic anhydrase 4Homo sapiens (human)
cell surfaceCarbonic anhydrase 4Homo sapiens (human)
membraneCarbonic anhydrase 4Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 4Homo sapiens (human)
transport vesicle membraneCarbonic anhydrase 4Homo sapiens (human)
secretory granule membraneCarbonic anhydrase 4Homo sapiens (human)
brush border membraneCarbonic anhydrase 4Homo sapiens (human)
perinuclear region of cytoplasmCarbonic anhydrase 4Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID238915Binding affinity towards human membrane associated carbonic anhydrase IV2005Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6
Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with organic phosphates and phosphonates.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (374)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990197 (52.67)18.7374
1990's83 (22.19)18.2507
2000's51 (13.64)29.6817
2010's26 (6.95)24.3611
2020's17 (4.55)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 50.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index50.19 (24.57)
Research Supply Index5.96 (2.92)
Research Growth Index4.43 (4.65)
Search Engine Demand Index83.44 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (50.19)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.26%)5.53%
Reviews15 (3.89%)6.00%
Case Studies6 (1.55%)4.05%
Observational0 (0.00%)0.25%
Other364 (94.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]